6:24 PM
 | 
Jan 27, 2016
 |  BC Extra  |  Clinical News

Genticel's ProCervix misses HPV endpoint

Genticel S.A. (Euronext:GTCL) said ProCervix ( GTL001) missed the primary endpoint in the European Phase II RHEIA-VAC trial, which evaluated the potential of the bivalent therapeutic vaccine to prevent cervical cancer by enhancing immune response to HPV. The vaccine failed to improve viral clearance at 12 months postvaccination vs. placebo (48.7% for ProCervix vs....

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >